Antengene

Antengene

制药业

Shanghai,Changning District 5,638 位关注者

Treating Patients Beyond Borders.

关于我们

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.

所属行业
制药业
规模
201-500 人
总部
Shanghai,Changning District
类型
上市公司
创立
2017
领域
抗肿瘤创新药物、新药开发和临床研究

地点

Antengene员工

动态

关联主页

相似主页

融资

Antengene 共 3 轮

上一轮

C 轮

US$97,000,000.00

Crunchbase 上查看更多信息